These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 9346879)
21. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Liu MY; Poellinger L; Walker CL Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296 [TBL] [Abstract][Full Text] [Related]
22. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. Stratmann R; Krieg M; Haas R; Plate KH J Neuropathol Exp Neurol; 1997 Nov; 56(11):1242-52. PubMed ID: 9370235 [TBL] [Abstract][Full Text] [Related]
24. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Knebelmann B; Ananth S; Cohen HT; Sukhatme VP Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397 [TBL] [Abstract][Full Text] [Related]
25. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Cohen HT; Zhou M; Welsh AM; Zarghamee S; Scholz H; Mukhopadhyay D; Kishida T; Zbar B; Knebelmann B; Sukhatme VP Biochem Biophys Res Commun; 1999 Dec; 266(1):43-50. PubMed ID: 10581162 [TBL] [Abstract][Full Text] [Related]
26. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. Datta K; Nambudripad R; Pal S; Zhou M; Cohen HT; Mukhopadhyay D J Biol Chem; 2000 Jul; 275(27):20700-6. PubMed ID: 10748176 [TBL] [Abstract][Full Text] [Related]
28. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. Gunaratnam L; Morley M; Franovic A; de Paulsen N; Mekhail K; Parolin DA; Nakamura E; Lorimer IA; Lee S J Biol Chem; 2003 Nov; 278(45):44966-74. PubMed ID: 12944410 [TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Clifford SC; Czapla K; Richards FM; O'Donoghue DJ; Maher ER Br J Cancer; 1998 May; 77(9):1420-8. PubMed ID: 9652757 [TBL] [Abstract][Full Text] [Related]
30. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Mukhopadhyay D; Datta K Semin Cancer Biol; 2004 Apr; 14(2):123-30. PubMed ID: 15018896 [TBL] [Abstract][Full Text] [Related]
31. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815 [TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Pause A; Lee S; Lonergan KM; Klausner RD Proc Natl Acad Sci U S A; 1998 Feb; 95(3):993-8. PubMed ID: 9448273 [TBL] [Abstract][Full Text] [Related]
34. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. Pal S; Datta K; Khosravi-Far R; Mukhopadhyay D J Biol Chem; 2001 Jan; 276(4):2395-403. PubMed ID: 11060301 [TBL] [Abstract][Full Text] [Related]
35. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531 [TBL] [Abstract][Full Text] [Related]
36. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495 [TBL] [Abstract][Full Text] [Related]
37. Von Hippel-Lindau disease. Sano T; Horiguchi H Microsc Res Tech; 2003 Feb; 60(2):159-64. PubMed ID: 12539169 [TBL] [Abstract][Full Text] [Related]
38. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. Jones MK; Szabó IL; Kawanaka H; Husain SS; Tarnawski AS FASEB J; 2002 Feb; 16(2):264-6. PubMed ID: 11772947 [TBL] [Abstract][Full Text] [Related]
39. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619 [TBL] [Abstract][Full Text] [Related]
40. High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. Mukhopadhyay D; Tsiokas L; Sukhatme VP Gene Expr; 1998; 7(1):53-60. PubMed ID: 9572397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]